How to monitor impurities and ensure consistent gene therapies
One of the biggest challenges in developing advanced therapy medicinal products and viral vaccines is ensuring and documenting that the downstream process consistently produces a safe product.
Neither ELISA, SDS PAGE, nor Western blotting can sufficiently identify and quantify process-related impurities in the complex products. And what’s more, these traditional methods offer only minimal monitoring of individual protein impurities.
Do you know the new solution (LC-MS) that more and more C> companies turn to?
In this webinar, you will learn how to quickly identify and quantify all proteins using only one assay – irrespective of the source of the proteins.YES, sign me up >>